# Cerebral microhemorrhages in a mouse model of sickle cell disease

## TL;DR

This study shows that sickle cell disease in mice causes increased brain microhemorrhages, which are linked to mast cells, suggesting a new treatment target.

## Contribution

The study identifies cerebral mast cells as a novel therapeutic target in sickle cell disease.

## Key findings

- SCD mice had 86% more cerebral microhemorrhages than controls.
- Mast cells were positively correlated with microhemorrhage number in SCD mice.
- Cerebral microvascular disease is significant in SCD progression.

## Abstract

Stroke in sickle cell disease (SCD) is often attributed to large vessel involvement in the disorder, whereas the contribution of cerebral microvascular disease has been less explored. In this study, we investigated the formation of cerebral microvascular lesions and the involvement of mast cells in a humanized SCD mouse model.

We studied hemorrhagic microvascular disease in a well-characterized mouse model of humanized transgenic sickle (HbSS-BERK) expressing >99% human sickle hemoglobin (HbS) and a control (HbAA-BERK) mouse model expressing normal human hemoglobin A (HbA). Mouse brains were analyzed by Prussian blue staining to detect cerebral microhemorrhage (CMH) formation. Mast cell identification was performed by toluidine blue staining.

SCD brain sections exhibited approximately 86% more CMH than controls (mean ± SE of 1.17 ± 0.22 vs. 0.63 ± 0.13 number/cm2, P = .02). Mast cells were positively correlated with CMH number in SCD mice (Spearman r = 0.42, P < .05), but not in control mice.

SCD mice demonstrated significantly increased CMH load compared with control mice, and SCD microhemorrhages were associated with the number of mast cells. These findings highlight the significance of cerebral microvascular disease in SCD and imply that cerebral mast cells may be a novel therapeutic target in SCD.